Inozyme Pharma Company Insiders
| INZY Stock | USD 1.44 0.02 1.37% |
Inozyme Pharma employs about 59 people. The company is managed by 13 executives with a total tenure of roughly 138 years, averaging almost 10.0 years of service per executive, having 4.54 employees per reported executive. Break down of Inozyme Pharma's management performance can provide insight into the company performance.
Inozyme |
Inozyme Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3569) % which means that it has lost $0.3569 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7942) %, meaning that it created substantial loss on money invested by shareholders. Inozyme Pharma's management efficiency ratios could be used to measure how well Inozyme Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Inozyme Pharma Workforce Comparison
Inozyme Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,090. Inozyme Pharma holds roughly 59.0 in number of employees claiming about 5% of equities under Health Care industry.
Inozyme Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inozyme Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inozyme Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Inozyme Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Douglas Treco few days ago Disposition of 25000 shares by Douglas Treco of Inozyme Pharma subject to Rule 16b-3 | ||
Sullivan Lynne Marie over two months ago Acquisition by Sullivan Lynne Marie of 9367 shares of Inozyme Pharma subject to Rule 16b-3 | ||
Harris Erik over three months ago Insider Trading | ||
Matthew Winton over three months ago Acquisition by Matthew Winton of 1710 shares of Inozyme Pharma at 4.45 subject to Rule 16b-3 | ||
Wenkert Deborah over three months ago Insider Trading | ||
Diaz Reinaldo M over six months ago Acquisition by Diaz Reinaldo M of 28000 shares of Inozyme Pharma at 4.4 subject to Rule 16b-3 | ||
Edwards Martin over six months ago Acquisition by Edwards Martin of 28000 shares of Inozyme Pharma at 4.4 subject to Rule 16b-3 | ||
Bolte Axel over six months ago Acquisition by Bolte Axel of 16000 shares of Inozyme Pharma at 6.18 subject to Rule 16b-3 |
Inozyme Pharma Notable Stakeholders
An Inozyme Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Inozyme Pharma often face trade-offs trying to please all of them. Inozyme Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Inozyme Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Douglas Treco | CEO Chairman | Profile | |
| Yves Sabbagh | Chairman VP | Profile | |
| Matthew Winton | Senior COO | Profile | |
| Henric Bjarke | VP COO | Profile | |
| Gayle Gironda | Senior Officer | Profile | |
| MA MS | Advisor Board | Profile | |
| MSc MBA | President, CoFounder | Profile | |
| MS MBA | CFO Officer | Profile | |
| Soojin Kim | Senior Officer | Profile | |
| Demetrios MD | Scientific CoFounder | Profile | |
| MBA MBA | Consultant | Profile | |
| Stefan Riley | Director Relations | Profile | |
| Stephen MBA | Consultant | Profile |
About Inozyme Pharma Management Performance
The success or failure of an entity such as Inozyme Pharma often depends on how effective the management is. Inozyme Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inozyme management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inozyme management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Inozyme Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.
Please note, the imprecision that can be found in Inozyme Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inozyme Pharma. Check Inozyme Pharma's Beneish M Score to see the likelihood of Inozyme Pharma's management manipulating its earnings.
Inozyme Pharma Workforce Analysis
Traditionally, organizations such as Inozyme Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Inozyme Pharma within its industry.Inozyme Pharma Manpower Efficiency
Return on Inozyme Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 5.5M | |
| Working Capital Per Employee | 3.1M | |
| Working Capital Per Executive | 14M |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.